Truist Securities Maintains Buy on Arcus Biosciences, Lowers Price Target to $44
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained its Buy rating on Arcus Biosciences (NYSE:RCUS) but has lowered the price target from $50 to $44.

June 24, 2024 | 1:43 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Truist Securities has maintained its Buy rating on Arcus Biosciences but has lowered the price target from $50 to $44.
The maintenance of the Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates a more cautious outlook on its near-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100